Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.
About Centogene N.V.
Centogene N.V. (Nasdaq: CNTG) is a global leader in the field of genetic diagnostics and multiomic testing services, specializing in rare and neurodegenerative diseases. Founded in 2006, the company has carved a niche in the life sciences industry by integrating advanced sequencing technologies with a robust biodatabank to provide data-driven insights that enable precise diagnosis, drug discovery, and development. Centogene's mission is to deliver life-changing answers to patients, physicians, and pharmaceutical companies worldwide, addressing unmet needs in the healthcare ecosystem.
Core Business Areas
Centogene operates across three primary domains:
- Diagnostics: The company offers a comprehensive portfolio of over 5,000 genetic and biochemical tests, including whole exome sequencing (WES), whole genome sequencing (WGS), and biomarker analyses. Its diagnostic solutions cover more than 19,000 genes, enabling early and accurate detection of over 2,500 rare diseases.
- Biodatabank: At the heart of Centogene's operations is its proprietary CENTOGENE Biodatabank, the world's largest real-world integrated multiomic data repository for rare and neurodegenerative diseases. This database includes over 850,000 patient samples from more than 120 countries, with a significant representation of non-European populations, making it a critical resource for understanding genetic diversity.
- Pharmaceutical Partnerships: Centogene collaborates with leading pharmaceutical companies to accelerate drug discovery and development. By leveraging its biodatabank and multiomic expertise, the company de-risks and expedites the clinical development of targeted therapies, particularly for orphan and neurodegenerative diseases.
Competitive Advantage
Centogene's competitive edge lies in its unique integration of diagnostics, data analytics, and pharmaceutical collaboration. The CENTOGENE Biodatabank serves as a cornerstone for its operations, enabling the identification of novel genetic variants and biomarkers. This data-driven approach not only facilitates accurate diagnostics but also supports the development of precision medicine solutions. Additionally, the company's partnerships with global pharmaceutical giants like Takeda and Evotec underscore its role as a trusted partner in the life sciences industry.
Market Significance
Operating at the intersection of healthcare and biotechnology, Centogene addresses critical gaps in the diagnostics and treatment of rare diseases. Its contributions extend beyond individual patient care to advancing global health insights through its extensive research and development efforts. The company's work has led to over 300 peer-reviewed publications, highlighting its commitment to scientific excellence and innovation.
Collaborative Ecosystem
Centogene's collaborative model includes partnerships with pharmaceutical companies, academic institutions, and healthcare providers. These collaborations focus on accelerating the development of novel therapies, improving patient outcomes, and expanding access to genetic testing. Notable initiatives include the ROPAD Study, which explores the genetic underpinnings of Parkinson's disease, and partnerships aimed at addressing lysosomal storage disorders and other rare conditions.
Future Outlook
With a steadfast commitment to innovation and patient-centric solutions, Centogene is poised to continue its leadership in the genetic diagnostics landscape. By integrating cutting-edge technologies with real-world data, the company aims to transform the diagnosis and treatment of rare and neurodegenerative diseases, ultimately contributing to a world healed of these conditions.
Centogene N.V. (Nasdaq: CNTG) has announced the pricing of a public offering of 3,500,000 common shares at $14.00 each, aiming to raise $28 million for the company and $21 million for selling shareholders. The offering includes 2,000,000 shares from the company and 1,500,000 shares from shareholders. The underwriters have a 30-day option to purchase an additional 525,000 shares. Proceeds will support research and development for orphan drug initiatives, working capital, and potential acquisitions. The offering is set to close around July 14, 2020.
Centogene N.V. (Nasdaq: CNTG) announced the publication of its paper titled ‘Rapid Large-Scale COVID-19 Testing During Shortages’ in Diagnostics. The study highlights innovative testing solutions amidst the COVID-19 pandemic, contributing valuable insights to the medical community. CEO Prof. Arndt Rolfs emphasized their commitment to high-quality molecular diagnostics, particularly in supporting widespread SARS-CoV-2 testing. The company aims to enhance patient care through reliable testing and has established a testing service at Frankfurt airport, reinforcing its role in addressing public health challenges.
Centogene N.V. (Nasdaq: CNTG) has initiated an underwritten public offering of 3.5 million common shares, consisting of 2 million shares from the company and 1.5 million from selling shareholders, with an additional 525,000 shares available for underwriters. Proceeds from the offering will fund research and development for orphan drug initiatives, working capital, and potential investments in complementary businesses. The offering is dependent on market conditions and a registration statement is pending effectiveness.
Centogene N.V. (Nasdaq: CNTG) has partnered with OESIS Network to provide COVID-19 screening for schools across the U.S. The partnership will utilize RT-PCR testing at affordable prices, aimed at facilitating the safe return of students and staff to campus. Up to 50,000 tests per week will be available, with potential for increased capacity. The initiative emphasizes privacy, utilizing anonymized sample collection. With a focus on quality and logistics, Centogene's services will support both public and independent schools, potentially funded through the Cares Act.
Centogene N.V. (Nasdaq: CNTG) announced that the FDA has granted Emergency Use Authorization for its SARS-CoV-2 RT-PCR test. This test is designed for qualitative detection of the virus using upper respiratory samples. CEO Prof. Arndt Rolfs emphasized the company's commitment to high-quality diagnostics to combat COVID-19. The test, intended for use in CENTOGENE's certified laboratories in Germany, aims to facilitate early diagnosis and support public health initiatives. The company collaborates with pharmaceutical partners to enhance testing efficacy.
CENTOGENE (NASDAQ: CNTG) has partnered exclusively with Lufthansa and Fraport to offer COVID-19 testing for passengers at Frankfurt Airport. This initiative aims to facilitate safe international travel as restrictions ease. The testing service is now available and will continue until July 31, 2021. Passengers can access a convenient walk-in testing center, obtaining results via a secure digital platform, essential for travels to countries requiring testing. This collaboration represents a significant step towards normalizing air travel amid the pandemic.
Centogene N.V. (Nasdaq: CNTG) announced the resignation of Supervisory Board member Christoph Ehlers, effective June 15, 2020, due to personal circumstances. Ehlers served over six years and contributed significantly to the company's growth. CEO Prof. Arndt Rolfs expressed gratitude for Ehlers' role and noted his ongoing involvement. Centogene specializes in rare diseases, leveraging real-world clinical and genetic data to aid patients and pharmaceutical companies, boasting a repository of 3.0 billion weighted data points from over 530,000 patients across 120 countries as of March 31, 2020.
Centogene N.V. (Nasdaq: CNTG) reported €12.1 million in revenues for Q1 2020, marking a 13% increase year-over-year. The company continues expanding its rare disease platform, with approximately 3 billion data points from over 530,000 patients. Despite the challenges posed by COVID-19, Centogene launched its CentoSwab™ testing kit and expanded testing capabilities. However, the company reported a comprehensive loss of €8.6 million, or €0.43 per share, compared to €5.2 million, or €0.33 per share, in Q1 2019. R&D and G&A expenses also increased significantly.
Centogene N.V. (Nasdaq: CNTG) announced it will report its financial results for Q1 2020 on June 15, 2020. The earnings call will take place at 8 a.m. EST, where the company will discuss its financial performance and outlook. Centogene focuses on rare diseases, utilizing a platform that integrates clinical and genetic data from approximately 500,000 patients across 120 countries. The company collaborates with over 39 pharmaceutical partners to enhance orphan drug development. Interested participants can access the call by dialing provided numbers or via the company's Investor Relations webpage.
Centogene N.V (Nasdaq: CNTG) announced on May 15, 2020, that Chief Business Officer Oved Amitay will resign effective May 31, 2020. He will be succeeded by Sun Kim, currently the Chief Strategy and IR Officer. Prof. Arndt Rolfs, CEO, expressed gratitude for Amitay's contributions to the growth of the Pharma business, emphasizing Kim’s extensive experience in strategy and commercial operations as beneficial for future collaborations. Centogene focuses on rare diseases, utilizing a platform with approximately 2.5 billion data points from around 500,000 patients worldwide as of December 31, 2019.
FAQ
What is the current stock price of Centogene N.V. Common Shares (CNTG)?
What is the market cap of Centogene N.V. Common Shares (CNTG)?
What does Centogene N.V. specialize in?
What is the CENTOGENE Biodatabank?
How does Centogene collaborate with pharmaceutical companies?
What types of tests does Centogene offer?
What makes Centogene unique in the diagnostics market?
What diseases does Centogene focus on?
Who are Centogene's key collaborators?
What is the ROPAD Study?
